Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$167.33 USD
+2.59 (1.57%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $167.32 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
JNJ 167.33 +2.59(1.57%)
Will JNJ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for JNJ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JNJ
3 Medical Stocks to Consider as Markets Take a Breather
JNJ or AZN: Which Pharma Giant is a Better Buy Post Q2 Results?
JNJ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Buy 5 Wide Moat Stocks to Enhance Your Portfolio Returns
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
Other News for JNJ
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
ClearBridge Value Portfolios Q2 2025 Commentary
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
European pharmaceutical stocks slip after Trump pushes for lower drug prices